Formats
  1. Journal Article (66871)
  2. Meeting Abstract (33621)
  3. Book Section (5097)
  4. Review (3759)
  5. Editorial (2172)
  6. Conference Paper (1526)
  7. Correspondence (666)
  8. Guidelines (662)
  9. Research Letter (548)
  10. Book Whole (344)
  11. Miscellaneous (339)
Groups
  1. Department of Medicine (39065)
  2. GSK Faculty (22476)
  3. Solid Tumor Oncology Division (22077)
  4. Surgery (21270)
  5. Survivorship Research (15773)
  6. Sloan Kettering Institute Faculty (15657)

More Groups

People
  1. Marc Ladanyi (1328)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1052)

More People

Years
  1. 2025 (2137)
  2. 2024 (5384)
  3. 2023 (5806)
  4. 2022 (6169)
  5. 2021 (5714)
  6. 2020 (5618)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4951)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2611)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13846)
  2. American Society of Clinical Oncology (9169)
  3. Springer (7194)
  4. Nature Publishing Group (6375)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5512)

More Publishers

Results (115605)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2a/2b multicenter study of AG-946 in patients with anemia due to lower-risk myelodysplastic syndromes
    Meeting Abstract

    Al-Samkari, H.; Fenaux, P.; Sekeres, M. A.; Stein, E.; Sallman, D. A.; Brunner, A. M.; Gurov, X. D.; Yin, O.; Frisbie, M.; Xiao, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Shah, N. N.; Wang, M. L.; Brown, J. R.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • MYLOX-1: An open-label, phase IIa study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral LOXL2 inhibitor, GB2064, in myelofibrosis
    Meeting Abstract

    Verstovsek, S.; Mascarenhas, J.; Rampal, R. K.; Cilloni, D.; Harrison, C.; Jacoby, B.; Slack, R. J.; Aslanis, V.; Singh, B.; Lindmark, B.
    Blood (2022)

    Fulltext@MSK | Save
  • Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (CML-CP)-H. Jean Khoury Cure CML Consortium study
    Meeting Abstract

    Atallah, E. L.; Visotcky, A.; Flynn, K. E.; Zhang, M. J.; Radich, J. P.; Yang, J.; Oehler, V. G.; Tantravahi, S. K.; Smith, B. D. D.; Ibarz, J. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term molecular testing and clinical response of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: 5-year follow-up from SIMPLICITY, a prospective, observational study
    Meeting Abstract

    Cortes, J. E.; Goldberg, S. L.; Paquette, R.; Williams, L. A.; Hehlmann, R.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D. R.; DeGutis, I. S.; McBride, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119
    Meeting Abstract

    Bar-Natan, M.; Mascarenhas, J.; Gerds, A. T.; Mesa, R.; Gupta, V.; Kremyanskaya, M.; Dougherty, M.; Fabris, F.; Johnson, K.; Yu, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Impact on tumour treatment and outcome of SARS-CoV-2 infection in 91 patients with primary CNS lymphoma: A real-life study of the international PCNSL Collaborative Group
    Meeting Abstract

    Calimeri, T.; Steffanoni, S.; Laurenge, A.; Fox, C. P.; Soussain, C.; Grommes, C.; Tisi, M. C.; Boot, J.; Crosbie, N.; Visco, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase Ib/II trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in refractory/recurrent primary (PCNSL) and secondary central nervous system lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Piotrowski, A.; Pentsova, E.; Gavrilovic, I.; Stone, J. B.; Lin, A.; Wongchai, V.; Madzsar, J. T.; Malani, R.; Nolan, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Escape from type II JAK2 inhibition in MPN depends on AXL/MAPK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J.; Ghosh, N.; Buczak, K.; Passweg, J.; Angelillo-Scherrer, A.; Dirnhofer, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term outcome of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and CREBBP mutational status
    Meeting Abstract

    Bantilan, K. S.; Rutherford, K.; McCarter, J.; Farnoud, N.; Arango-Ossa, J. E.; Papaemmanuil, E.; Zelenetz, A. D.
    Blood (2022)

    Fulltext@MSK | Save